Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.

Inclusion Criteria:

• Aged between 18 and 75, both sex;
• Able to sign informed consent.

Exclusion Criteria:

• Pregnant women and those who are implanted with pacemakers, stents or any other metal devices.